Here's another article
[FONT="]A number of first generation SARMs are now in phase I trials. These compounds are being positioned for early efficacy trials for osteoporosis, frailty, cancer cachexia, and aging-associated functional limitations. Also, SARMs that potently inhibit gonadotropins, but spare the prostate, would be attractive as candidates for male contraception. The use of SARMs for the treatment of androgen deficiency syndromes in men has been proposed; the relative advantages of SARMs over testosterone for this indication are not readily apparent. Many biological functions of testosterone, especially its effects on libido and behavior, bone, and plasma lipids require its aromatization to estrogen; because the currently available SARMs are neither aromatized nor 5-alpha reduced, these compounds would face an uphill regulatory bar for approval as they would be required to show efficacy and safety in many more domains of androgen action than has been required of testosterone formulations.[/FONT]
[FONT="]------------------------------ FROM THE SAME ARTICLE, LATER:[/FONT]
[FONT="]Structural modifications of aryl propionamide analogs bicalutamide and hydroxyflutamide led to the discovery of the first generation of SARMs. Compounds S1 and S4 in this series bind AR with high affinity, and demonstrate tissue selectivity in the Hershberger assay that utilizes castrated rat model (35–37). In this castrated rat model, both S1 and S4 prevented castration induced atrophy of levator ani muscle, and acted as weak agonists in the prostate (35, 37, 38). At a dose of 3 mg/kg/day, S4 partially restored the prostate weight to < 20% of intact, but fully restored the levator ani weight, skeletal muscle strength, bone mineral density, bone strength, and lean body mass, and suppressed LH and FSH (39, 40). S4 also prevented ovariectomy-induced bone loss in female rat model of osteoporosis (41). The ability of SARMs to promote both muscle strength and bone mechanical strength constitutes a unique advantage over other therapies for osteoporosis that only increase bone density.[/FONT]
[FONT="]S1 and S4 are partial agonists; thus, in intact male rats (37), S1 and S4 compete with endogenous androgens and act as antagonists in prostate, such SARMs with antagonistic or low intrinsic activity in prostate might be useful in the treatment of BPH or prostate cancer. The suppressive effects of this class of SARMs on gonadotropin secretion in rats suggest potential application for male contraception (37).
i can do this all day long, the point is, that what you read is complete nonsense... [/FONT]